Market Cap
$2.4B
IMNM
Immunome Inc.
$21.08 ▲ +0.91%
Prev close $20.89Market cap$2.4B
ConsensusStrong Buy
12-mo target$35.20 (+67.0%)
▲ Bullish
Analyst conviction 10/10
Insider Selling Cluster (2 insiders)High Impact Filing (7/10)22 New Institutional Positions11 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on IMNM right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (95%)
Inst. Holders
50 funds
Inst. Value
$1.6B
Inst. Activity
22 buys / 11 sells
Insider Activity
$116.9K buy / $16.2M sell
Insider Net $
-$16.1M
SEC Reports
13
Price chart 30d -22.9%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Apr 28, 2027 fda_pdufa
Oct 1, 2026 SEC PDUFA: IMNM — varegacestat in desmoid tumors — 2027-04-28
FDA target action date 2027-04-28 for IMNM (Immunome Inc.). Drug: varegacestat. Indication: desmoid
Stifel initiates coverage on IMNM at Hold
ANALYST-UPGRADE — Impact 4/10
Alliance Global Partners initiates coverage on IMNM at Buy
ANALYST-UPGRADE — Impact 4/10
Sep 11, 2026 Insider
Higgins Jack sold 13,200 shares
Chief Scientific Officer @ $25.32 ($334.2K)
Sep 11, 2026 Insider
Higgins Jack acquired via exercise 18,000 shares
Chief Scientific Officer @ $1.35 ($24.3K)
Sep 11, 2026 Insider
Higgins Jack gifted 8,800 shares
Chief Scientific Officer
Jun 30, 2026 Inst.
JPMORGAN CHASE & CO — TRIM
1,848,548 shares ($39.0M)
Jun 30, 2026 Inst.
GOLDMAN SACHS GROUP INC — ADD
1,512,489 shares ($32.0M)
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
95% rate it Buy or better · 20 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Oct 1, 2026 | Stifel | INITIATE | Hold | 54% |
| Sep 21, 2026 | Alliance Global Partners | INITIATE | Buy | 42% |
| Sep 10, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Aug 12, 2026 | Truist Securities | MAINTAIN | Buy | 55% |
| Aug 12, 2026 | Wedbush | MAINTAIN | Outperform | 57% |
| Jul 21, 2026 | Wedbush | REITERATE | Outperform | 57% |
| Jun 12, 2026 | Wedbush | REITERATE | Outperform | 57% |
| May 28, 2026 | Truist Securities | MAINTAIN | Buy | 55% |
| May 28, 2026 | Barclays | INITIATE | Overweight | 54% |
| May 15, 2026 | Leerink Partners | MAINTAIN | Outperform | 49% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 5 | 14 | 1 | 0 | 0 | 95% | |
| Aug 1, 2026 | 5 | 14 | 1 | 0 | 0 | 95% | |
| Jul 1, 2026 | 5 | 14 | 1 | 0 | 0 | 95% | |
| Jun 1, 2026 | 6 | 14 | 1 | 0 | 0 | 95% | |
| May 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| Apr 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| Mar 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| Feb 1, 2026 | 6 | 12 | 1 | 0 | 0 | 95% |
Price targets
Where 15 covering analysts think IMNM trades over the next 12 months.
$35.20 +67.0% upside Strong Buy
Current$21.08 Low$24.00 Median$36.00 High$40.00 15 analysts
$24.00$40.00
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
13 SEC filing reports analyzed · 4 bullish, 1 bearish, 2 mixed, 6 neutral · avg impact 4.0/10.
BULLISHANALYST-UPGRADE3/10
Barclays initiates IMNM to Overweight — PT $36 (+66%)
May 28, 2026
BULLISHANALYST-UPGRADE4/10
Stifel initiates coverage on IMNM at Hold
Oct 1, 2026
BULLISHANALYST-UPGRADE4/10
Alliance Global Partners initiates coverage on IMNM at Buy
Sep 21, 2026
NEUTRALCLUSTER4/10
Two insiders at Immunome sold a total of $2.54M in shares over a week, led by the Chief Business Off
Aug 12, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Apr 28, 2027
fda_pdufa
PDUFA: IMNM — varegacestat in desmoid tumors — 2027-04-28
FDA target action date 2027-04-28 for IMNM (Immunome Inc.). Drug: varegacestat. Indication: desmoid tumors. PDUFA target action date set for April 28,
Sep 25, 2026
short_volume
Short Volume: IMNM — 73.1% short (0.7M / 1.0M)
Short: 748,527 | Exempt: 144 | TRF Vol: 1,023,728 | Short Ratio: 73.1% | Off-exchange volume (dark pool + OTC)
Sep 24, 2026
short_volume
Short Volume: IMNM — 64.1% short (0.7M / 1.1M)
Short: 725,314 | Exempt: 1,693 | TRF Vol: 1,131,445 | Short Ratio: 64.1% | Off-exchange volume (dark pool + OTC)
Aug 25, 2026
short_volume
Short Volume: IMNM — 57.7% short (0.3M / 0.6M)
Short: 327,822 | Exempt: 356 | TRF Vol: 567,934 | Short Ratio: 57.7% | Off-exchange volume (dark pool + OTC)
Aug 19, 2026
earnings_calendar
IMNM Q2 2026 Earnings Scheduled — 2026-08-19
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.59 | $-0.71–$-0.41 | 9.5% | +0.6% | 3↑ 7↓ | $0.0B | 14 |
| Next Q | $-0.61 | $-0.75–$-0.38 | 19.9% | +0.9% | 2↑ 7↓ | $0.0B | 14 |
| Current FY | $-2.29 | $-2.56–$-2.02 | 5.7% | +0.9% | 0↑ 10↓ | $0.0B | 13 |
| Next FY | $-2.43 | $-2.90–$-1.85 | -5.9% | +2.1% | 1↑ 7↓ | $0.1B | 12 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.588 | — |
| 7d ago | $-0.588 | — |
| 30d ago | $-0.592 | +0.004 |
| 60d ago | $-0.558 | -0.030 |
| 90d ago | $-0.558 | -0.030 |
Institutional ownership
Which big funds own IMNM (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $1.6B total value (74,950,914 shares) as of 2026-Q2. Top holders: FMR, BlackRock,, STATE. Net buying activity: 22 institutions added/increased vs 11 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| FMR LLC | 16,987,553 | $360.0M | 22.7% | — |
| BlackRock, Inc. | 8,805,492 | $186.6M | 11.7% | — |
| STATE STREET CORP | 5,494,625 | $116.4M | 7.3% | ADD +39.6% |
| WELLINGTON MANAGEMENT GROUP LLP | 5,210,216 | $110.4M | 7.0% | DOUBLED +406.4% |
| PRIMECAP MANAGEMENT CO/CA/ | 4,581,431 | $97.1M | 6.1% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 4,551,289 | $96.4M | 6.1% | — |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 4,346,139 | $92.1M | 5.8% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 2,754,889 | $58.4M | 3.7% | — |
| MORGAN STANLEY | 2,407,942 | $51.0M | 3.2% | ADD +66.3% |
| JPMORGAN CHASE & CO | 1,848,548 | $39.0M | 2.5% | TRIM -33.5% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| JPMORGAN CHASE & CO | TRIM | 2,777,836 | 1,848,548 | -33.5% | $39.0M |
| GOLDMAN SACHS GROUP INC | ADD | 1,101,476 | 1,512,489 | +37.3% | $32.0M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | 1,006,975 | 1,348,979 | +34.0% | $28.6M |
| Woodline Partners LP | TRIM | 1,575,398 | 1,000,398 | -36.5% | $21.2M |
| MetLife Investment Management, LLC | DOUBLED | 55,857 | 859,076 | +1438.0% | $18.2M |
| Candriam S.C.A. | ADD | 539,882 | 680,132 | +26.0% | $14.4M |
| MARSHALL WACE, LLP | TRIM | 1,480,788 | 500,537 | -66.2% | $10.6M |
| Qube Research & Technologies Ltd | DOUBLED | 188,229 | 439,186 | +133.3% | $9.3M |
| DIMENSIONAL FUND ADVISORS LP | DOUBLED | 33,408 | 367,967 | +1001.4% | $7.8M |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 68,902 | 251,102 | +264.4% | $5.3M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
13 insiders, 50 transactions. Net -$16.1M — $116.9K bought, $16.2M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 11, 2026 | Higgins Jack | Chief Scientific Officer | SELL | 13,200 | $25.32 | $334.2K |
| Sep 11, 2026 | Higgins Jack | Chief Scientific Officer | EXERCISE | 18,000 | $1.35 | $24.3K |
| Sep 11, 2026 | Higgins Jack | Chief Scientific Officer | GIFT | 8,800 | — | — |
| Aug 12, 2026 | Barchas Isaac | Director | SELL | 11,048 | $27.25 | $301.1K |
| Aug 11, 2026 | Barchas Isaac | Director | SELL | 62,291 | $26.23 | $1.6M |
| Aug 10, 2026 | Barchas Isaac | Director | SELL | 10,125 | $26.07 | $264.0K |
| Aug 7, 2026 | Barchas Isaac | Director | SELL | 15,248 | $26.06 | $397.4K |
| Aug 6, 2026 | Barchas Isaac | Director | SELL | 20,840 | $26.06 | $543.1K |
| Aug 4, 2026 | Horn Kinney | CHIEF BUSINESS OFFICER | SELL | 90,616 | $25.09 | $2.3M |
| Aug 4, 2026 | Horn Kinney | CHIEF BUSINESS OFFICER | EXERCISE | 40,250 | $10.60 | $426.6K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for IMNM.
Shares short
16,244,557
Settlement Sep 15, 2026
Change vs prior
+3.9%
Semi-monthly cycle
Days to cover
20.6
At avg daily volume
Of shares outstanding
≈14.3%
Estimate — not % of float
All IMNM filing & press-release reports (13)
- Barclays initiates IMNM to Overweight — PT $36 (+66%)May 28, 2026
- Stifel initiates coverage on IMNM at HoldOct 1, 2026
- Alliance Global Partners initiates coverage on IMNM at BuySep 21, 2026
- CLUSTER reportAug 12, 2026
- CLUSTER reportAug 10, 2026
- CLUSTER reportJul 9, 2026
- CLUSTER reportJul 7, 2026
- CLUSTER reportJul 7, 2026
- CLUSTER reportJul 3, 2026
- 8-K reportMay 12, 2026
- DEFA14A reportApr 24, 2026
- CLUSTER reportApr 1, 2026
- CLUSTER reportMar 31, 2026